Harvard Bioscience (FRA:HBI0) EBIT: €-3.50 Mil (TTM As of Mar. 2026)


FRA:HBI0 Harvard Bioscience Inc FRA:HBI0
48 GF Score
Price €4.08
GF Value €13.30
! 6 Warning Signs
View Full Analysis

What is Harvard Bioscience EBIT?

Harvard Bioscience FRA:HBI0 48 EBIT is €-3.50 Mil as of Mar. 2026. GuruFocus rates FRA:HBI0 with a GF Score™ of 48/100 and a GF Value™ of €13.30. The stock has 6 warning signs investors should review.

Harvard Bioscience's earnings before interest and taxes (EBIT) for the three months ended in Mar. 2026 was €-1.37 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Mar. 2026 was €-3.50 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Harvard Bioscience's annualized ROC % for the quarter that ended in Mar. 2026 was -5.67%. Harvard Bioscience's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was -20.91%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Harvard Bioscience's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was -6.22%.


Harvard Bioscience  (FRA:HBI0) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Harvard Bioscience's annualized ROC % for the quarter that ended in Mar. 2026 is calculated as:

ROC % (Q: Mar. 2026 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Dec. 2025 ) + Invested Capital (Q: Mar. 2026 ))/ count )
=-3.248 * ( 1 - 0% )/( (57.906 + 56.703)/ 2 )
=-3.248/57.3045
=-5.67 %

where

Note: The Operating Income data used here is four times the quarterly (Mar. 2026) data.

2. Joel Greenblatt's definition of Return on Capital:

Harvard Bioscience's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 is calculated as:

ROC (Joel Greenblatt) %(Q: Mar. 2026 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Dec. 2025  Q: Mar. 2026
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-5.464/( ( (10.213 + max(16.376, 0)) + (10.033 + max(15.63, 0)) )/ 2 )
=-5.464/( ( 26.589 + 25.663 )/ 2 )
=-5.464/26.126
=-20.91 %

where Working Capital is:

Working Capital(Q: Dec. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(13.701 + 17.767 + 2.36) - (3.119 + 2.944 + 11.389)
=16.376

Working Capital(Q: Mar. 2026 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(12.605 + 19.207 + 3.117) - (4.573 + 3.171 + 11.555)
=15.63

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Harvard Bioscience's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Mar. 2026 )
=-3.499/56.246
=-6.22 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Harvard Bioscience EBIT Related Terms


Harvard Bioscience EBIT Historical Data

* Premium members only.

The historical data trend for Harvard Bioscience's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Harvard Bioscience EBIT Chart

Harvard Bioscience Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.24 -6.26 0.95 -7.76 -44.81

Harvard Bioscience Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -46.12 -1.27 -0.14 -0.72 -1.37

FRA:HBI0 vs FEMY, RVP, MLSS: EBIT Comparison

For the Medical Instruments & Supplies subindustry, Harvard Bioscience's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Harvard Bioscience EV-to-EBIT vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Harvard Bioscience's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Harvard Bioscience's EV-to-EBIT falls into.


FRA:HBI0
48GF Score
Harvard Bioscience Inc FRA:HBI0
EBIT is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Harvard Bioscience EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-3.50 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT →
What does a EBIT of €-3.50 Mil mean?
Harvard Bioscience (FRA:HBI0) has a EBIT of €-3.50 Mil as of Mar. 2026. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Harvard Bioscience.
Is Harvard Bioscience's EBIT too high?
Harvard Bioscience's current EBIT is €-3.50 Mil. Overall, Harvard Bioscience has a GF Score™ of 48/100, reflecting its overall financial health beyond just this single metric.
How does Harvard Bioscience's EBIT compare to FEMY and RVP?
Harvard Bioscience's EBIT of €-3.50 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Medical Devices & Instruments company?
A good EBIT depends on the Medical Devices & Instruments industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Harvard Bioscience. Harvard Bioscience's current EBIT is €-3.50 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Harvard Bioscience stock overvalued right now?
Harvard Bioscience (FRA:HBI0) has a current EBIT of €-3.50 Mil. The stock's GF Value™ is €13.30, compared to a current price of €4.08 — trading 69.3% below its estimated fair value. The current EBIT is €-3.50 Mil. Harvard Bioscience's overall GF Score™ is 48/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For Harvard Bioscience (FRA:HBI0), the current EBIT is €-3.50 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Harvard Bioscience (FRA:HBI0) Overvalued in 2026?

Based on GuruFocus' analysis, Harvard Bioscience stock appears to be undervalued. The current stock price of €4.08 is trading 69.3% below its estimated GF Value™ of €13.30.

Key valuation signals for FRA:HBI0:

  • EBIT: €-3.50 Mil
  • GF Value™: €13.30 vs. price of €4.08 (69.3% below fair value)
  • GF Score™: 48/100 with 6 warning signs

No single metric tells the full story. See the FRA:HBI0 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Harvard Bioscience Business Description

Other Exchanges HBIO:USA
Address 84 October Hill Road, Suite 10, Holliston, MA, USA, 01746
Harvard Bioscience Inc is a developer, manufacturer, and seller of technologies, products, and services that enable advances in life science applications, including research, drug and therapy discovery, bioproduction, and preclinical testing. The company organizes its product line into two product families: Cellular and Molecular Technologies (CMT) and Preclinical. The CMT product family supports molecular, cellular, organ, and organoid research, as well as bioproduction and in vitro testing, while the Preclinical product family provides products for preclinical research and testing, including data collection and analysis for safety and regulatory compliance. Its geographical segments include the Americas, Europe, Middle East and Africa, and Asia.
48GF Score

Get the complete analysis for FRA:HBI0

EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€4.08
Price
€13.30
GF Value